92,882 results match your criteria Hepatitis C


Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions.

Am J Gastroenterol 2020 Jul;115(7):1022-1023

Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Over the past several years, single- and multi-center case series have reported on the successful use of livers from hepatitis C virus (HCV)-antibody positive and HCV-viremic donors to HCV-negative recipients. Several authors have studied not only the efficacy of this practice but also its cost-effectiveness of transplanting HCV-infected organs to HCV-negative donors. However, previous studies had limited follow-up and had not examined transplants beyond the beginning of 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000649DOI Listing

The Inflammatory Relationship between Hepatitis C Virus with Coronary and Carotid Atherosclerosis.

Cardiol Rev 2020 Jun 18. Epub 2020 Jun 18.

Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY.

Hepatitis C Virus (HCV), a global health concern, has been linked to various hepatic and extrahepatic deleterious manifestations. Several observational studies, have either supported the increased likelihood of coronary and carotid atherosclerosis after infection with hepatitis C virus, or refuted it. To date, there has been no clear consensus to support either train of thought, as randomized, controlled clinical trials have not been completed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CRD.0000000000000314DOI Listing

Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis.

Arch Virol 2020 Jul 2. Epub 2020 Jul 2.

Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.

Coinfections of hepatitis C virus (HCV) and/or hepatitis B virus (HBV) with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) are associated with high morbidity and mortality and poor prognosis. The main objective of this study was to evaluate the prevalence of HCV and/or HBV coinfections among people who inject drugs (PWID) and female sex workers (FSWs) who live with HIV/AIDS worldwide. Data sources were searched from January 2008 to October 2018 in different databases, including PubMed, Scopus, Web of Science, Embase, and Ovid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00705-020-04716-1DOI Listing

Factors Associated With Testing for Hepatitis C Infections Among a Commercially Insured Population of Persons With HIV, United States 2008-2016.

Open Forum Infect Dis 2020 Jun 6;7(6):ofaa222. Epub 2020 Jun 6.

Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Background: Hepatitis C virus (HCV) infection is an important public health problem among people with HIV. People with HIV who are coinfected with HCV infection are at increased risk for cirrhosis, liver failure, and hepatitis C-related mortality; as such, national guidelines recommend that persons with HIV be tested for HCV infection.

Methods: Data from the 2003-2017 IBM Watson Health MarketScan database were used for this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofaa222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320833PMC

Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.

Open Forum Infect Dis 2020 Jun 26;7(6):ofaa196. Epub 2020 May 26.

Department of Infectious Diseases, Hôpital Henri Mondor, Université Paris-Est, Créteil, France.

Background: Injecting drug use is a major driver of hepatitis C virus (HCV) spread worldwide, and the World Health Organization (WHO) has identified people who inject drugs (PWID) as a key population to target for HCV screening and care. Point-of-care (POC) hepatitis C tests and dried blood spot (DBS) sampling offer benefits for the management of patients with HCV infection by increasing HCV testing and linkage to care in different nonclinical settings. The aims of this prospective study were to evaluate the feasibility and the acceptability of use HCV ribonucleic acid (RNA) POC and fingerstick DBS testing in social-medical risk-reduction centers and to describe the cascade of care among PWID in France. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofaa196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314587PMC

A Recent Human Immunodeficiency Virus Outbreak Among People Who Inject Drugs in Munich, Germany, Is Associated With Consumption of Synthetic Cathinones.

Open Forum Infect Dis 2020 Jun 27;7(6):ofaa192. Epub 2020 May 27.

Division of HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.

Background: Needle and syringe sharing among people who inject drugs (PWID) can result in a rapid regional spread of a human immunodeficiency virus (HIV) variant. Such outbreaks have been identified recently in several countries and have raised public health attention because of an association with new psychoactive substances (NPS).

Methods: Dried serum spots from approximately 60% of newly diagnosed HIV cases in Germany in 2013-2018 were received together with statutory notification data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ofid/ofaa192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314588PMC

AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.

Clin Liver Dis (Hoboken) 2020 Jun 30;15(6):211-212. Epub 2020 Jun 30.

Section of Gastroenterology and Hepatology Baylor College of Medicine Houston TX.

Watch a video presentation of this article Watch an interview with the author. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cld.943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326632PMC

Pathogen-associated selection on innate immunity genes (TLR4, TLR7) in a neotropical rodent in landscapes differing in anthropogenic disturbance.

Heredity (Edinb) 2020 Jul 2. Epub 2020 Jul 2.

Institute of Evolutionary Ecology and Conservation Genomics, Ulm University, 89069, Ulm, Germany.

Toll-like receptors (TLRs) form part of the innate immune system and can recognize structurally conserved pathogen-associated molecular pattern (PAMP) molecules. Their functional importance in the resistance to pathogens has been documented in laboratory experimental settings and in humans. TLR diversity, however, has been rarely investigated in wildlife species. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41437-020-0331-yDOI Listing

Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.

Gut Liver 2020 Jul 6. Epub 2020 Jul 6.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Background/aims: Extrahepatic comorbidities and comedication are important to consider in the treatment of chronic hepatitis C (CHC) patients with direct-acting antivirals (DAAs) due to the risk of drug-drug interaction (DDI) and the effect of comorbidities on clinical outcomes. This study aimed to investigate the detailed profiles of comorbidities and comedication among Korean CHC patients.

Methods: All adult patients (≥18 years old) with a primary diagnostic code of CHC in 2013 were selected from the National Health Insurance claims database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5009/gnl19387DOI Listing

Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol.

BMC Public Health 2020 Jul 2;20(1):1048. Epub 2020 Jul 2.

University of North Carolina Project-China, 1 Global Health Center Office, 2nd Floor of Lao Gan Building, No. 7 Lujing Road, Yuexiu District, Guangzhou City, Guangdong Province, Guangzhou, China.

Background: Hepatitis C virus (HCV) is a growing public health problem with a large disease burden worldwide. In China many people living with HCV are unaware of their hepatitis status and not connected to care and treatment. Crowdsourcing is a technique that invites the public to create health promotion materials and has been found to increase HIV testing uptake, including in China. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12889-020-09152-zDOI Listing

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.

Lancet Oncol 2020 Jul;21(7):947-956

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.

Background: Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30224-2DOI Listing

The emerging role and significance of circular RNAs in viral infections and antiviral immune responses: possible implication as theranostic agents.

RNA Biol 2020 Jul 2. Epub 2020 Jul 2.

Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore (UOL) , Lahore, Pakistan.

Circular RNAs (circRNAs) are ubiquitously expressed, covalently closed rings, produced by pre-mRNA splicing in a reversed order during post-transcriptional processing. Circularity endows 3'-5'-linked circRNAs with stability and resistance to exonucleolytic degradation which raises the question whether circRNAs may be relevant as potential therapeutic targets or agents. High stability in biological systems is the most remarkable property and a major criterion for why circRNAs could be exploited for a range of RNA-centered medical applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15476286.2020.1790198DOI Listing

Age and Risk-Factor Based Serologic Screening for Hepatitis C Virus among an Urban, High-Risk Population.

J Viral Hepat 2020 Jul 2. Epub 2020 Jul 2.

Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.

Hepatitis C virus (HCV) screening among individuals born between 1945 and 1965 (i.e. birth cohort) may augment risk-factor based screening. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13359DOI Listing

Twelve Weeks of Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Trials.

Hepatol Res 2020 Jul 2. Epub 2020 Jul 2.

First Department of Internal Medicine, Gastroenterology and Hepatology, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.

Aim: The combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for the treatment of various hepatitis C (HCV) genotypes across many countries. This article presents an integrated analysis of three prospective phase 2/3 trials in the Asia-Pacific region to evaluate the efficacy and safety of 12-weeks of LDV/SOF in HCV genotype 2 patients without cirrhosis or with compensated cirrhosis.

Methods: 200 patients were included in the integrated analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.13546DOI Listing

Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study.

J Infect Dis 2020 Jul 2. Epub 2020 Jul 2.

Institute of Tropical Medicine HIV/STD Reference Laboratory, Nationalestraat, Antwerp, Belgium.

Background: Hepatitis C virus (HCV) screening is critical to HCV elimination efforts. Simplified diagnostics are required for low-resource settings and difficult-to-reach populations. This retrospective study assessed performance of rapid diagnostic tests (RDTs) for detection of HCV antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/infdis/jiaa389DOI Listing

Trauma-informed care training with HIV and related community service workers: Short and long term effects on attitudes.

Psychol Serv 2020 Jul 2. Epub 2020 Jul 2.

Traumatic Stress Institute of Klingberg Family Centers.

Although the experience of trauma is a widespread, global phenomenon, individuals living with HIV, who are two-spirit, lesbian, gay, bisexual, transgender, queer+ (2SLGBTQ+), who use injection drugs, and/or who have marginalized status, are disproportionately affected (Harris & Fallot, 2006; Hopper, Bassuk, & Olivet, 2009; Seedat, 2012). The need for trauma competent service provision, meaning integrating psychoeducation about trauma, and knowledge of its prevalence, impact, and outcomes, is clear. Numerous HIV service and affiliated agencies in Ontario requested a Trauma-Informed Care workshop for their staff and volunteers, and the current project reports on the outcomes of this workshop. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1037/ser0000465DOI Listing

Hepatitis c virus and chronic kidney disease.

Expert Rev Gastroenterol Hepatol 2020 Jul 2:1-11. Epub 2020 Jul 2.

Weill Cornell Medical College , New York, Qatar.

Introduction: Hepatitis C virus (HCV) infection is associated with an increased incidence and progression of chronic kidney disease (CKD), as well as higher mortality in CKD and renal transplant patients. Direct acting antiviral agents (DAAs) have revolutionized the treatment of HCV, with viral eradication attained in 90-100% of treated patients. DAAs have an excellent safety and tolerability profile in CKD and renal transplant patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474124.2020.1776111DOI Listing

"Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries.

Int J Health Policy Manag 2020 Jun 1;9(6):229-232. Epub 2020 Jun 1.

Department of Public Health & Policy, London School of Hygiene and Tropical Medicine, London, UK.

Chronic hepatitis C virus (HCV) infection, associated with severe liver disease and cancer, affects 70 million people worldwide. New treatments with direct-acting-antivirals offer cure for about 95% of affected individuals; however, treatment costs may be prohibitive in both the poorest and richest nations. Opting for cure may require sacrificing essential household assets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15171/ijhpm.2019.135DOI Listing

Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring.

Egypt Heart J 2020 Jul 1;72(1):37. Epub 2020 Jul 1.

Cardiology Department, Faculty of Medicine, Ain Shams University, Abbassia square, Abbasia, Cairo, 11566, Egypt.

Background: Direct-acting antiviral agents (DAAs) cure patients with hepatitis C virus (HCV) infection. Concerns have arisen the occurrence of significant bradyarrhythmias during treatment with DAAs. The aim of this study was to assess the impact of a DAA combination for the treatment of HCV infection on heart rate, rhythm, and heart rate variability (HRV) using 24-h ECG monitoring. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43044-020-00070-4DOI Listing

Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocholangiocarcinoma.

Therap Adv Gastroenterol 2020 20;13:1756284820935189. Epub 2020 Jun 20.

Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.

Introduction: Hepatocholangiocarcinoma (HCC-ICC) is a rare tumor presenting the histologic characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). As there is no consensus on it management, the therapeutic strategy rests on the specific treatments for HCC or ICC. Programmed cell death 1 (PD-1) inhibitors showed encouraging results in the second line treatment of HCC after sorafenib but it efficacy in HCC-ICC has never been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756284820935189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307284PMC

Cholangiocarcinoma Metastasis to the Spine and Cranium.

Ochsner J 2020 ;20(2):197-203

Department of Neurosurgery, Ochsner Clinic Foundation, New Orleans, LA.

Cholangiocarcinoma (CCC), a rare tumor arising from the viscera, has a poor prognosis. Although CCC is prone to metastasis, spread to the cranium and spine is exceedingly rare. Treatment for metastatic disease is palliative, with total resection of the primary lesion the only cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31486/toj.18.0142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310165PMC
January 2020

Severe Bradycardia Induced by Sofosbuvir and Amiodarone which Resolved after the Discontinuation of Both Drugs.

Intern Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Emergency and Critical Care Medicine, Tokyobay Urayasu Ichikawa Medical Center, Japan.

Amiodarone, prescribed for cardiac conditions, including dysrhythmia, is associated with bradycardia. However, few reports have demonstrated that bradycardia is observed when amiodarone is used in combination with sofosbuvir, a direct-acting antiviral drug for chronic hepatitis C. We herein report the case of a male patient in his 70s with chronic atrial fibrillation and prostatic hyperplasia and was also taking amiodarone, who experienced severe bradycardia and syncope a day after taking sofosbuvir and ribavirin for chronic hepatitis C. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4488-20DOI Listing

Correction for Kwon et al., "Hepatitis C Virus Core Protein Modulates Endoglin (CD105) Signaling Pathway for Liver Pathogenesis".

J Virol 2020 Jul 1;94(14). Epub 2020 Jul 1.

Departments of Internal Medicine, Saint Louis University, St. Louis, Missouri, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/JVI.00629-20DOI Listing

One-step diagnosis. A key tool for the elimination of hepatitis C.

Rev Esp Enferm Dig 2020 Jul 2;112:513-514. Epub 2020 Jul 2.

Aparato Digestivo, Hospital Universitario Fundación Alcorcón, España.

Hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma, as well as the primary indication for liver transplant in Europe. The highly effective direct-acting antivirals currently available make it possible to achieve the hepatitis C elimination targets set by the World Health Organization. For this, population screening and one-step diagnosis are fundamental strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17235/reed.2020.7201/2020DOI Listing

Legal and Ethical Challenges in Developing a Dutch Nationwide Hepatitis C Retrieval Project (CELINE).

Int J Health Policy Manag 2020 Mar 7. Epub 2020 Mar 7.

Department of Gastroenterology & Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.

In 2016 the World Health Organization (WHO) called upon nations worldwide to eliminate viral hepatitis. Due to suboptimal hepatitis C virus (HCV) therapies in the past, many patients could not be treated or cured. With the current options, all patients can be treated and >90% is cured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.34172/ijhpm.2020.33DOI Listing

A Serological Survey of Selected Papua New Guinea Blood Donors for Hepatitis B and Related Co-Infections.

Trop Med Infect Dis 2020 Jun 29;5(3). Epub 2020 Jun 29.

Medical and Veterinary Sciences, College of Public Health, James Cook University, Townsville, Queensland 4811, Australia.

Hepatitis B virus (HBV) infection is a serious problem and earlier studies in Papua New Guinea have reported a high prevalence of hepatitis B virus infection. These studies were undertaken using insensitive tests and before an expanded immunization program. The current HBV status is therefore uncertain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/tropicalmed5030108DOI Listing

Significant improvement in portal-systemic liver failure symptoms and successful management of portal-splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy.

Hepatol Res 2020 Jul 1. Epub 2020 Jul 1.

Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube-Yamaguchi, 7558505, Japan.

Aim: To describe a case of hepatitis C virus-related decompensated cirrhosis with portal-systemic liver failure and refractory encephalopathy that was successfully managed with a combination of interventional radiology and pharmacotherapy to improve hepatic function including hyperammonemia and to control portal-splenic venous hemodynamics with hepatic venous pressure gradient (HVPG) monitoring.

Case Presentation: A man in his late 50s presented with a Child-Pugh score of 13, Model for End-Stage Liver Disease-sodium (MELD-Na) score of 19, and blood ammonia level of 185 μg/dL. He underwent balloon-occluded retrograde transvenous obliteration (BRTO) followed by partial splenic embolization (PSE) and non-selective beta-blocker (NSBB) administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hepr.13545DOI Listing

Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir.

Arq Neuropsiquiatr 2020 Jun;78(6):342-348

Instituto de Infectologia Emilio Ribas, Departamento de Doenças Infecciosas, Grupo de Hepatites, São Paulo SP, Brazil.

Background: Hepatitis C can be defined as an infectious disease that develops an inflammatory activity, which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression.

Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir.

Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0004-282X20200022DOI Listing

Can we offer more for cognitive impairment in patients with chronic hepatitis C?

Authors:
Ugo Nocentini

Arq Neuropsiquiatr 2020 Jun;78(6):319-320

Università di Roma "Tor Vergata", Dipartimento di Scienze Cliniche e Medicina Traslazionale, Roma, Italia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/0004-282X20200055DOI Listing

Assessing the Risk of HIV and Hepatitis C among Internally Displaced Persons in Georgia.

Authors:
Joshua Elbaz

Ann Glob Health 2020 Jun 24;86(1):66. Epub 2020 Jun 24.

Boston College, US.

Background: Georgia is leading one of the world's first hepatitis C (HCV) elimination programs alongside interventions to combat a HIV epidemic concentrated among high-risk groups. Although progress has been substantial, neither strategy accounts for the nearly 150,000 internally displaced persons residing in collective centers (CC-IDPs) who are susceptible to deeply integrated risk environments that could promote infection. Achieving dedicated goals for HCV elimination and HIV suppression requires a clear understanding of the risks facing CC-IDPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5334/aogh.2671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319078PMC

Successful Treatment of Hepatitis C Virus Infection Using Direct-Acting Antiviral Agents (DAAs) in Adolescents with Kidney Transplantation: A Case Series.

Int J Nephrol Renovasc Dis 2020 8;13:139-146. Epub 2020 Jun 8.

Department of Child Health, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Introduction: Hepatitis C virus (HCV) infection is common among end-stage renal disease patients undergoing hemodialysis. The standard treatment for HCV infection has been interferon-ribavirin combination prior to renal transplantation. However, compared to direct-acting antiviral agents (DAAs), the risk of graft rejection is higher with interferon therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJNRD.S248632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292374PMC

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed.

Infect Drug Resist 2020 18;13:1873-1880. Epub 2020 Jun 18.

Tropical Medicine and Gastroenterology Department, Alrajhi University Hospital, Assiut University, Assiut, Egypt.

Purpose: In interferon-free era, direct-acting antiviral agents (DAAs) have achieved high eradication rates with an excellent safety profile since revolutionized the management of hepatitis c virus (HCV) patients. Published papers have suggested a possible increased incidence of hepatocellular carcinoma (HCC) after successful DAAs treatment. Other papers have been published about the problem but without conclusive results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IDR.S241948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308127PMC

B protected: from vertical HCV transmission?

Gut 2020 Jun 30. Epub 2020 Jun 30.

Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/gutjnl-2020-321364DOI Listing

Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.

Mol Cancer Ther 2020 Jun 30. Epub 2020 Jun 30.

Hunterian Neurosurgical Research Laboratory, Department of Neurosurgery, Johns Hopkins University School of Medicine

Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma with a proclivity for systemic dissemination, leading many patients to present with advanced-stage disease and fail available treatments. There is a notable lack of targeted therapies for NPC, despite working knowledge of multiple proteins with integral roles in NPC cancer biology. These proteins include EZH2, Snail, eIF4E, and IMPDH, which are all overexpressed in NPC and correlated with poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0572DOI Listing

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.

Subst Abuse Treat Prev Policy 2020 Jun 30;15(1):44. Epub 2020 Jun 30.

Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.

Background: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatment uptake after the introduction of DAAs among patients receiving OAT in Sweden and Norway. We also aimed to evaluate predictors of DAAs treatment among OAT patients in both countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13011-020-00286-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325258PMC

Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review.

Subst Abuse Treat Prev Policy 2020 Jun 30;15(1):45. Epub 2020 Jun 30.

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Room T420, Toronto, Ontario, M5S 2S1, Canada.

Liver cirrhosis and other chronic liver diseases are usually compartmentalized into separate categories based on etiology (e.g., due to alcohol, virus infection, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13011-020-00287-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325038PMC

microRNA-99a Restricts Replication of Hepatitis C Virus by Targeting mTOR and de novo Lipogenesis.

Viruses 2020 Jun 27;12(7). Epub 2020 Jun 27.

The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

In this study, we investigated the role of microRNA-99a (miR-99a) in hepatitis C virus (HCV) replication and lipogenesis in hepatocytes. Cell-culture-derived HCV (HCVcc) infection caused down-regulation of miR-99a in Huh-7 cells, and the relative levels of miR-99a were significantly lower in the sera of the HCV-infected patients than in those of healthy controls. Transfection of miR-99a-5p mimics resulted in a decrease in the intracellular and secreted HCV RNA levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v12070696DOI Listing

[Unsolved issues of pregnancy in liver cirrhosis].

Ter Arkh 2019 Apr 15;91(4):114-117. Epub 2019 Apr 15.

Obstetric Clinic, University Hospital "Dr. Georgi Stranski", Department of obstetrics and gynecology, Medical University.

Pregnancy in patients with liver cirrhosis and portal hypertension occurs very rare, because of their significantly derailed reproductive functions. Тhe risks for the mother and the fetus are connected with worsening of the portal hypertension, progression of decompensated liver cirrhosis and development of its complications: liver failure, ascites, hepatorenal syndrome, hepatic encephalopathy and variceal hemorrhage, and with increased incidence of spontaneous abortions and abnormal uterine bleeding. The decision for continuation of the pregnancy in cirrhotic patients must be based on individual approach and a multidisciplinary team consisting of obstetricians, hepatologists, anesthesiologists, surgeons and hematologists must participate in the therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.04.000145DOI Listing

[Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis].

Ter Arkh 2018 Nov 15;90(11):67-73. Epub 2018 Nov 15.

A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health.

Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of decompensation (with the development of liver failure and portal hypertension) in cirrhotic patients during the course of DAAs-therapy of hepatitis C. The authors present contemporary views and their own assumptions about the possible mechanisms of the hepatic decompensation associated with DAAs-therapy in patients with liver cirrhosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh201890114-73DOI Listing
November 2018

Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.

Am J Med 2020 Jun 27. Epub 2020 Jun 27.

Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, USA; Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Background: The opioid epidemic has been associated with an increase in hepatitis C virus (HCV) infections. Federally qualified health centers (FQHCs) have a high burden of hepatitis C disease and could serve as venues to enhance testing and treatment.

Methods: We estimated clinical outcomes and the cost-effectiveness of hepatitis C testing and treatment at US FQHCs using individual-based simulation modeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjmed.2020.05.029DOI Listing

The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.

PLoS One 2020 30;15(6):e0235445. Epub 2020 Jun 30.

Burnet Institute, Melbourne, Victoria, Australia.

Background: Hepatitis C elimination will require widespread access to treatment and responses at the health-service level to increase testing among populations at risk. We explored changes in hepatitis C testing and the cascade of care before and after the introduction of direct-acting antiviral treatments in Victoria, Australia.

Methods: De-identified clinical data were retrospectively extracted from eighteen primary care clinics providing services targeted towards people who inject drugs. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235445PLOS

Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.

JAMA Netw Open 2020 Jun 1;3(6):e208081. Epub 2020 Jun 1.

Department of Medicine, The Pennsylvania State University College of Medicine, Hershey.

Importance: Direct-acting antiviral (DAA) therapy for hepatitis C is highly effective but expensive. Evidence is scarce on whether DAA therapy reduces downstream medical costs.

Objective: To examine the association of DAA therapy with posttreatment medical costs among Medicare beneficiaries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.8081DOI Listing

Colombian experience in the management of hepatitis C.

Liver Int 2020 Jun 29. Epub 2020 Jun 29.

Liver Transplant Unit, Fundacion Santa Fe de Bogota, Bogota, Colombia.

In a past issue of the journal, Schroeder et al. discuss the experience and prospects of hepatitis C in different countries; Colombia, however, was left out. Our country has had an agreement with the Pan American Health Organization (PAHO) since 2010 to participate in a regional fund for the acquisition of strategic public health products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14582DOI Listing

Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China.

Arch Virol 2020 Jun 29. Epub 2020 Jun 29.

Department of Clinical Laboratory, The Second People's Hospital of Yibin, Yibin, 644000, Sichuan, People's Republic of China.

The hepatitis C virus (HCV) NS5B protein is an RNA-dependent RNA polymerase that is required for viral genome replication and constitutes the most important target region for drugs being developed as direct-acting antivirals (DAAs) against HCV genotype 1. However, the extreme genetic variability leading to drug resistance mutations and genetic barriers has dramatically compromised the effectiveness of DAA therapy. The purpose of this study was to analyze the genetic variability of NS5B polymerase in HCV patients from different provinces of China to identify the impact of these resistance sites on genetic barriers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00705-020-04713-4DOI Listing

Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.

J Comput Aided Mol Des 2020 Jun 30. Epub 2020 Jun 30.

LASSBio - Laboratório de Avaliação e Síntese de Substâncias Bioativas, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, Avenida Carlos Chagas Filho 373, Rio de Janeiro, RJ, ZIP 21941-910, Brazil.

Herein, the LASSBio Chemical Library is presented as a valuable source of compounds for screening to identify hits suitable for subsequent hit-to-lead optimization stages. A feature of the LASSBio Chemical Library worth highlighting is the fact that it is a smart library designed by medicinal chemists with pharmacological activity as the main priority. The great majority of the compounds part of this library have shown in vivo activity in animal models, which is an indication that they possess overall favorable bioavailability properties and, hence, adequate pharmacokinetic profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10822-020-00327-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324290PMC

Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data.

Sci Rep 2020 Jun 29;10(1):10521. Epub 2020 Jun 29.

Predictive Analytics, Real World Solutions, IQVIA, London, N1 9JY, UK.

Hepatitis C virus (HCV) remains a significant public health challenge with approximately half of the infected population untreated and undiagnosed. In this retrospective study, predictive models were developed to identify undiagnosed HCV patients using longitudinal medical claims linked to prescription data from approximately ten million patients in the United States (US) between 2010 and 2016. Features capturing information on demographics, risk factors, symptoms, treatments and procedures relevant to HCV were extracted from patients' medical history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-67013-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324575PMC

HCV infection and the risk of head and neck cancer: A meta-analysis.

Oral Oncol 2020 Jun 26;109:104869. Epub 2020 Jun 26.

Department of Neurosciences, Section of Otolaryngology, University of Padova, Treviso, Italy. Electronic address:

Recent evidence has consistently suggested a role for HCV in the etiology of head and neck squamous cell carcinoma (HNSCC), but the conclusions of these studies have often been limited by small sample size. Therefore, a meta-analysis was performed to summarize present evidence on the association between HCV infection and HNSCC. After screening citations from literature search, eight observational studies investigating the association between HCV and cancer(s) of either oral cavity, oropharynx, hypopharynx or larynx were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oraloncology.2020.104869DOI Listing

Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention.

Drug Alcohol Depend 2020 Jun 12;213:108116. Epub 2020 Jun 12.

Yale University School of Public Health, 60 College Street, New Haven, Connecticut, 06510, USA.

Background: Co-located treatment for hepatitis C virus (HCV) infection for patients with opioid use disorder (OUD) within an opioid treatment program (OTP) addresses gaps in the HCV care continuum. Few reports have analyzed outcomes related to OUD treatment, such as retention, associated with co-located HCV treatment.

Methods: Patients (n = 89) treated for OUD and chronic HCV infection in a Northeast US OTP from January 2014 through July 2017 were compared to control patients (n = 199) being treated for OUD and diagnosed with but not treated for HCV during the same period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drugalcdep.2020.108116DOI Listing

[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].

Ter Arkh 2019 Aug 15;91(8):67-74. Epub 2019 Aug 15.

Yevdokimov Moscow State University of Medicine and Dentistry.

Aim: Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C.

Materials And Methods: The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistance - associated substitutions Y93C/H/N/S and/or L31F/M/V/I. Patients were treated with narlaprevir 200 mg QD, ritonavir 100 mg QD and daclatasvir 60 mg QD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.08.000384DOI Listing

[The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus].

Ter Arkh 2020 Apr 27;92(2):34-42. Epub 2020 Apr 27.

Sechenov First Moscow State Medical University (Sechenov University).

Aim: To study liver function and portal hypertension, incidence and risk factors of liver-related complications, including hepatocellular carcinoma (HCC), in patients with HCV-related liver cirrhosis achieved sustained virologic response (SVR) after direct-acting antiviral therapy.

Materials And Methods: Patients with HCV-related liver cirrhosis were followed up after achievement SVR with assessment of liver function parameters, portal hypertension, Model for End-stage Liver Disease (MELD) and Сhild Pugh (CP) scores, complications development, including HCC, every 36 months. The median follow-up duration was 24 [18; 30] months after end of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2020.02.000511DOI Listing